Literature DB >> 20516056

Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm.

J-J Hung1, W-J Jeng, W-H Hsu, S-F Lin, C-C Hsieh, B-S Huang, M-H Huang, J-S Liu, T-Y Chou, Y-C I Wu.   

Abstract

Significant heterogenity of stage IB (sixth edition of the TNM staging system) nonsmall cell lung cancer (NSCLC) has been identified, and further subclassification according to tumour size has been proposed. The aim of this study is to evaluate the prognostic factors in patients with resected stage IB NSCLC > 3 cm. From January 1980 to December 2000, 525 patients underwent surgical resection for stage IB NSCLC > 3 cm at Taipei Veterans General Hospital, Taipei, Taiwan. The clinicopathological characteristics of these patients were retrospectively reviewed. The 5- and 10-yr overall survival rates were 44.9% and 27.3%, respectively. Age (p < 0.001), tumour size (p = 0.002), extent of pulmonary resection (p = 0.002), histological type (p = 0.005) and number of mediastinal lymph nodes dissected/sampled (p = 0.004) were significant predictors for overall survival in multivariate analysis. Patients with tumour size >7 cm, or > 5 to ≤ 7 cm, had a worse survival than those with tumour size > 3 to ≤ 5 cm. However, visceral pleural invasion did not influence overall survival. Stage IB NSCLC with a diameter > 3 cm may be subclassified according to tumour size regardless of visceral pleural invasion.

Entities:  

Mesh:

Year:  2010        PMID: 20516056     DOI: 10.1183/09031936.00014109

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  1 in total

1.  Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Catherine Bonham; Cara Hrusch; Paul Nolan; Wesley Klejch; Shashi Bellam; Uday Mehta; Kiran Thakrar; Janelle Vu Pugashetti; Aliya N Husain; Steven M Montner; Christopher M Straus; Rekha Vij; Anne I Sperling; Imre Noth; Mary E Strek; Jonathan H Chung
Journal:  Am J Respir Crit Care Med       Date:  2019-03-15       Impact factor: 21.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.